Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Securities Fraud Worries Reduced In Supreme Court Omnicare Ruling

This article was originally published in The Tan Sheet

Executive Summary

High court finds that a corporation’s statement of opinion is not actionable unless company did not sincerely believe it; ruling makes it harder for plaintiffs to file stock fraud claims.

You may also be interested in...



Clovis, CEO Mahaffy Settle SEC Investor Fraud Charges Over Rociletinib Efficacy Claims

Clovis, CEO Patrick Mahaffy and former CFO Erie Mast will pay more than $20m to settle charges by the SEC that the company misled investors on the efficacy of rociletinib. Clovis raised $298m in a public stock offering during the timeframe SEC says it misled investors.

P&G Asks For Higher Class Action Floor In Align Class Certification Appeal

Procter & Gamble petitions the Supreme Court to overturn a decision giving class action certification to a complaint alleging the firm deceived consumers with its “snake oil” Align probiotic. If the court overturns the lower court, the action could make class action certifications more difficult.

Securities Fraud Class Action Suits Could Grow After Amgen’s Supreme Court Loss

Supreme Court rules 6-3 that plaintiffs do not need to prove that a company’s misrepresentations were material at the class certification stage; investors allege Amgen misrepresented the safety of Aranesp and Epogen.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel